AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25719252 — intervention group
Group type: COMPARATOR
Intervention: All devices
Number of subjects: 69
Study 24434526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (12 mg/d)
Number of subjects: 583
Study 24434526 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine patch (9.5 mg/24 h)
Number of subjects: 583
Study 21718259 — intervention group
Group type: EXPERIMENTAL
Intervention: SPA (Seattle Protocol for Activity)
Number of subjects: 273
Study 21718259 — intervention group
Group type: EXPERIMENTAL
Intervention: SPA+HP
Number of subjects: 273
Study 21718259 — intervention group
Group type: COMPARATOR
Intervention: RMC (Routine Medical Care)
Number of subjects: 273
Study 21718259 — intervention group
Group type: COMPARATOR
Intervention: HP (Health Promotion)
Number of subjects: 273
Study 19303012 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/d) for 6 weeks
Number of subjects: 42
Study 19303012 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label budesonide (9 mg/d) for 6 additional weeks after placebo
Number of subjects: 42
Study 19303012 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 42
Study 17570997 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost and brinzolamide
Number of subjects: 22
Study 17570997 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 22
Study 14766438 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone treatment
Number of subjects: 36
Study 14766438 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 11148439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepean Dyspepsia Index quality-of-life scales
Number of subjects: 589
Study 11148439 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item short form (SF; short form-Nepean Dyspepsia Index)
Number of subjects: 589
Study 11148439 — intervention group
Group type: COMPARATOR
Intervention: Nepean Dyspepsia Index
Number of subjects: 589
Study 9779838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 20
Study 9779838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A plus hydroxychloroquine
Number of subjects: 20
Study 9779838 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 7512131 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 304
Study 7512131 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 304
Study 3418376 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy
Number of subjects: 43
Study 3418376 — intervention group
Group type: COMPARATOR
Intervention: Control (no BCG therapy)
Number of subjects: 43
Study 30816167 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis in urine
Number of subjects: 41
Study 30816167 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing on urine
Number of subjects: 41
Study 30816167 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation levels in urine
Number of subjects: 41
Study 28318077 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded maternal voice played for 10 minutes before and after venipuncture
Number of subjects: 60
Study 28318077 — intervention group
Group type: COMPARATOR
Intervention: No sound therapy intervention (Control)
Number of subjects: 60
Study 26024727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day for 9 days
Number of subjects: 18
Study 26024727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg FC + hCRH
Number of subjects: 8
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg FC + hCRH
Number of subjects: 8
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg FC + hCRH
Number of subjects: 8
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg FC + hCRH
Number of subjects: 8
Study 23011321 — intervention group
Group type: COMPARATOR
Intervention: Placebo + hCRH
Number of subjects: 8
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg FC + placebo
Number of subjects: 8
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg FC + placebo
Number of subjects: 8
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg FC + placebo
Number of subjects: 8
Study 23011321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg FC + placebo
Number of subjects: 8
Study 23011321 — intervention group
Group type: COMPARATOR
Intervention: Placebo p.o. + placebo i.v.
Number of subjects: 8
Study 21530292 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐Clips
Number of subjects: 30
Study 21530292 — intervention group
Group type: COMPARATOR
Intervention: Standard 8/0 polypropylene running suture
Number of subjects: 30
Study 18261121 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraTech implants
Number of subjects: 54
Study 18261121 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark implants
Number of subjects: 54
Study 18261121 — intervention group
Group type: COMPARATOR
Intervention: Implant sites
Number of subjects: 54
Study 18261121 — intervention group
Group type: COMPARATOR
Intervention: Tooth sites
Number of subjects: 54
Study 18261121 — intervention group
Group type: COMPARATOR
Intervention: Presence of Staphylococcus aureus
Number of subjects: 54
Study 16987366 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized pre‐operative information and enforced mobilization and nutrition
Number of subjects: 79
Study 16987366 — intervention group
Group type: COMPARATOR
Intervention: Conventional peri‐operative care
Number of subjects: 79
Study 14586921 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid iontophoresis plus physiotherapy (n=18)
Number of subjects: 36
Study 14586921 — intervention group
Group type: COMPARATOR
Intervention: Sham acetic acid iontophoresis plus physiotherapy (n=18)
Number of subjects: 36
Study 11029681 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (tricyclics, selective serotonin reuptake inhibitors, S-adenosylmethionine)
Number of subjects: 16
Study 11029681 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 16
Study 9415344 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus fenofibrate
Number of subjects: 29
Study 9415344 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin plus cholestyramine
Number of subjects: 29
Study 8233289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg BW IVIG
Number of subjects: 100
Study 8233289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg BW IVIG
Number of subjects: 100
Study 8233289 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 100
Study 3157346 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam, 1 g intramuscularly
Number of subjects: 0
Study 3157346 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin, 2 g intramuscularly
Number of subjects: 0
Study 31931894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine and placebo (n = 68)
Number of subjects: 204
Study 31931894 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine and placebo (n = 68)
Number of subjects: 204
Study 31931894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine and paroxetine (n = 68)
Number of subjects: 204
Study 31307050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention study with trained listeners analyzing recordings
Number of subjects: 119
Study 30293689 — intervention group
Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (6.5wt%; PA)
Number of subjects: 60
Study 30293689 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde (5wt%; GA)
Number of subjects: 60
Study 30293689 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA-activated riboflavin (0.5wt%; RB)
Number of subjects: 60
Study 30293689 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study 26467779 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (6 sessions/week)
Number of subjects: 245
Study 26467779 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 sessions/week)
Number of subjects: 245
Study 25269896 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function monitoring guided antiplatelet therapy (adjusted aspirin to 200 mg/d if AA-induced IPA <50%, adjusted clopidogrel to 150 mg/d if ADP-induced IPA <30%)
Number of subjects: 384
Study 25269896 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual antiplatelet therapy (standard treatment)
Number of subjects: 384
Study 23217188 — intervention group
Group type: EXPERIMENTAL
Intervention: MAKS therapy (motor stimulation, practice of activities of daily living, cognitive stimulation), 2 hours, 6 days a week for 12 months.
Number of subjects: 61
Study 23217188 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard nursing home care)
Number of subjects: 61
Study 23217188 — intervention group
Group type: EXPERIMENTAL
Intervention: MAKS therapy
Number of subjects: 61
Study 23217188 — intervention group
Group type: COMPARATOR
Intervention: MAKS therapy and Control group
Number of subjects: 61
Study 20052694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention including parenting skills and social skills training between 7 and 9 years of age
Number of subjects: 895
Study 20052694 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 895
Study 18262450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone-gabapentin
Number of subjects: 338
Study 18262450 — intervention group
Group type: COMPARATOR
Intervention: Placebo-gabapentin
Number of subjects: 338
Study 15984630 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% cream and gel
Number of subjects: 30
Study 15984630 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene cream 0.05% and 0.1%
Number of subjects: 30
Study 15984630 — intervention group
Group type: COMPARATOR
Intervention: Negative control product
Number of subjects: 30
Study 12906339 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolithic osmotic tablet system (MOTS) containing nifedipine, 30 mg
Number of subjects: 11
Study 12906339 — intervention group
Group type: COMPARATOR
Intervention: Commercial Adalat osmotic tablet system containing nifedipine, 30 mg
Number of subjects: 11
Study 10648749 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 164
Study 10648749 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 164
Study 9315427 — intervention group
Group type: EXPERIMENTAL
Intervention: Median-based t-like statistic
Number of subjects: 0
Study 9315427 — intervention group
Group type: COMPARATOR
Intervention: Paired t-test
Number of subjects: 0
Study 1527273 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy without active medication
Number of subjects: 52
Study 3901422 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 0
Study 3901422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30783259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (oral) for 3 months
Number of subjects: 40
Study 30783259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29931076 — intervention group
Group type: EXPERIMENTAL
Intervention: Motolimod
Number of subjects: 195
Study 29931076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 27058159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 188
Study 27058159 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 188
Study 27058159 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 188
Study 24556428 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-serving packages (SSPs)
Number of subjects: 64
Study 24556428 — intervention group
Group type: COMPARATOR
Intervention: Standard packages (STPs)
Number of subjects: 64
Study 22694905 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy plus D-cycloserine (DCS)
Number of subjects: 0
Study 22694905 — intervention group
Group type: COMPARATOR
Intervention: Exposure therapy plus placebo
Number of subjects: 0
Study 20643006 — intervention group
Group type: EXPERIMENTAL
Intervention: Open functional neck dissection technique on the primary tumour side
Number of subjects: 25
Study 20643006 — intervention group
Group type: COMPARATOR
Intervention: Functional neck dissection on the other side (control group)
Number of subjects: 25
Study 20643006 — intervention group
Group type: EXPERIMENTAL
Intervention: Open functional neck dissection technique
Number of subjects: 25
Study 20643006 — intervention group
Group type: COMPARATOR
Intervention: Functional neck dissection (control group)
Number of subjects: 25
Study 18648963 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (twice weekly for 6 weeks)
Number of subjects: 21
Study 11369675 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 45
Study 11369675 — intervention group
Group type: COMPARATOR
Intervention: Old control subjects
Number of subjects: 45
Study 11369675 — intervention group
Group type: COMPARATOR
Intervention: Young control subjects
Number of subjects: 45
Study 11369675 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 9432038 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-10010 (10 microg/kg)
Number of subjects: 52
Study 9432038 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-10010 (100 microg/kg)
Number of subjects: 52
Study 9432038 — intervention group
Group type: COMPARATOR
Intervention: No BB-10010 (Control)
Number of subjects: 52
Study 8517172 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT reuptake inhibitors
Number of subjects: 219
Study 8517172 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (tricyclic antidepressant)
Number of subjects: 219
Study 2948737 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine infusion
Number of subjects: 6
Study 2948737 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine infusion
Number of subjects: 6
Study 2948737 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 29698416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (n = 38)
Number of subjects: 72
Study 29698416 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 34)
Number of subjects: 72
Study 27549382 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity 4 Everyone (PA4E1) intervention
Number of subjects: 837
Study 27549382 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity practices (Control)
Number of subjects: 837
Study 26009023 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 600
Study 26009023 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational computer program (MC)
Number of subjects: 600
Study 26009023 — intervention group
Group type: COMPARATOR
Intervention: Supervision as usual (SAU)
Number of subjects: 600
Study 26009023 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MI, MC, SAU)
Number of subjects: 600
Study 23653149 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 MHC class I‐restricted melanoma peptides (12 MP)
Number of subjects: 175
Study 23653149 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 MHC class I‐restricted melanoma peptides plus a tetanus peptide (group B)
Number of subjects: 175
Study 23653149 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 melanoma helper peptides (6 MHP) to stimulate helper T lymphocytes (HTL) (group C)
Number of subjects: 175
Study 23653149 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 melanoma helper peptide (6 MHP) alone (group D)
Number of subjects: 175
Study 23653149 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study 23653149 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 175
Study 23653149 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune response to 6 MHP
Number of subjects: 175
Study 20691795 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 416
Study 20691795 — intervention group
Group type: COMPARATOR
Intervention: Disease-modifying anti-rheumatic drug treatment
Number of subjects: 416
Study 18647806 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pegvisomant (PEG‐V)
Number of subjects: 20
Study 18647806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16671434 — intervention group
Group type: EXPERIMENTAL
Intervention: High SjO2 (SjO2 > 75%, H-group; n = 10)
Number of subjects: 19
Study 16671434 — intervention group
Group type: COMPARATOR
Intervention: Normal SjO2 (SjO2 <= 75%, N-group; n = 9)
Number of subjects: 19
Study 12795573 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy challenge intervention
Number of subjects: 216
Study 12795573 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 216
Study 10894309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-service (FFS)
Number of subjects: 429
Study 10894309 — intervention group
Group type: COMPARATOR
Intervention: Health Maintenance Organizations (HMOs)
Number of subjects: 429
Study 8676825 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (VLPD) with ketoacids (KA)
Number of subjects: 8
Study 8676825 — intervention group
Group type: COMPARATOR
Intervention: Very-low-protein diet (VLPD) with essential amino acids (EAA)
Number of subjects: 8
Study 1473292 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of moderate exercise training
Number of subjects: 10
Study 1473292 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of detraining
Number of subjects: 10
Study 1473292 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary phase)
Number of subjects: 10
Study 31961448 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 0
Study 31961448 — intervention group
Group type: EXPERIMENTAL
Intervention: Model averaging via reversible jump markov chain monte carlo (MCMC)
Number of subjects: 0
Study 31961448 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds of TNE identified from compliant groups at each dose level
Number of subjects: 0
Study 30488542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly for 16 weeks
Number of subjects: 0
Study 30488542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29430253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Shen Guo Lao Nian Granule (SGLNG)
Number of subjects: 240
Study 29430253 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-dose Shen Guo Lao Nian Granule (SGLNG)
Number of subjects: 240
Study 29430253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Shen Guo Lao Nian Granule (SGLNG)
Number of subjects: 240
Study 29430253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 240
Study 25678361 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated chronoFLO4
Number of subjects: 361
Study 25678361 — intervention group
Group type: COMPARATOR
Intervention: Conventional FOLFOX2
Number of subjects: 361
Study 25678361 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-dependent covariate (TDC) analysis
Number of subjects: 361
Study 23988786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 mg kg(‐1) body mass of pseudoephedrine
Number of subjects: 10
Study 23988786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 mg kg(‐1) body mass of pseudoephedrine
Number of subjects: 10
Study 23988786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21923964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90
Study 21923964 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Number of subjects: 90
Study 19473813 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper article about the study
Number of subjects: 7233
Study 19473813 — intervention group
Group type: EXPERIMENTAL
Intervention: More favorably written newspaper article
Number of subjects: 7233
Study 19473813 — intervention group
Group type: COMPARATOR
Intervention: No newspaper article
Number of subjects: 7233
Study 19473813 — intervention group
Group type: COMPARATOR
Intervention: Original newspaper article
Number of subjects: 7233
Study 18767578 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Shenque (CV 8) combined with local electroacupuncture at Dubi (ST 35), Neixiyan (EX‐LE 5), Yanglingquan (GB 34) and Ashi points.
Number of subjects: 60
Study 18767578 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion at Shenque (CV 8) combined with local electroacupuncture at the same points.
Number of subjects: 60
Study 15943593 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 15943593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 12680748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 44
Study 12680748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10493678 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 kDa protein of Yersinia enterocolitica O:3
Number of subjects: 76
Study 10493678 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-19 kDa IgG antibodies
Number of subjects: 76
Study 10493678 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-19 kDa IgA antibodies
Number of subjects: 76
Study 10493678 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies to Yersinia outer membrane protein (YOP)
Number of subjects: 76
Study 10493678 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA antibodies to YOP
Number of subjects: 76
Study 8762385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand searching by both authors
Number of subjects: 105
Study 8762385 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent assessment of topics of the reports
Number of subjects: 105
Study 8762385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand searching of the journal
Number of subjects: 105